David Roth

David Roth is presented as a nephrologist in Miami and as one of the principal medical figures behind the volume’s examination of hepatitis C virus infection in chronic kidney disease, dialysis, and kidney transplantation. His significance lies less in a personal narrative than in the architecture of the evidence: through editorial responsibility, clinical guidance, original outcome research, and repeated citation, he helps turn HCV status into a sequence of consequential clinical questions—how infection is confirmed, how liver injury is staged, who remains eligible for kidney transplantation, how waiting-list risk is monitored, and when the hazards of treatment or immunosuppression alter the balance of choice.

Identity and Institutional Role

David Roth is identified as the volume editor and is associated with Miami, Florida. He also appears as a co-author with Roy Bloom of the chapter on selecting and managing HCV-infected patients for the kidney transplant waiting list. The chapter is affiliated with the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine, placing Roth within a clinical setting where renal replacement therapy, transplant assessment, and HCV management meet.

His editorial role gives him a position broader than that of a single-study investigator. The volume treats HCV as a systemic disease capable of affecting the liver while also inducing autoimmune, dermatological, and renal disease. Its organizing purpose is therefore interdisciplinary: it brings together infection, nephrology, dialysis practice, transplantation, and the renal complications of HIV/HCV coinfection. Roth’s work belongs to this same connective structure, translating virological status into decisions about organs, waiting time, surveillance, and survival.

Roth is also listed as a contributor to the volume’s chapter on kidney transplantation in patients with HCV infection, written with Jose M. Morales and Roy Bloom. His name appears again in the chapter’s references and in the address material identifying his Division of Nephrology and Hypertension. These repeated appearances establish him as both a visible institutional representative and an active participant in the clinical argument developed across the book.

Waiting-List Selection and Surveillance

Roth and Roy Bloom’s chapter begins from the recognition that HCV infection is common among patients with end-stage renal disease and is associated with poorer survival in both dialysis and transplant populations. Its central practical problem is not simply whether a candidate has antibodies, but whether the candidate has active viremia and how far liver disease has progressed. The chapter states that approximately 10–25% of pre-kidney-transplant candidates have advanced liver injury—Metavir stage 3 or 4 disease, including cirrhosis—when evaluated by biopsy.

The proposed assessment proceeds in layers. Candidates should initially be screened for anti-HCV antibody and, according to local prevalence, active viremia by nucleic acid testing. Chronic infection requires both anti-HCV antibodies and detectable HCV RNA; antibody positivity alone does not distinguish resolved infection from ongoing infection. For patients with active infection, liver biopsy remains the gold standard for staging despite clinicians’ concerns about platelet dysfunction in chronic uremia. The result determines whether kidney-alone transplantation remains appropriate or whether established or decompensated cirrhosis warrants referral to a liver-transplant team for consideration of simultaneous liver-kidney transplantation.

Roth’s clinical framework extends beyond the initial listing decision. Because waiting times in some United States regions approach five to seven years, a patient considered suitable for kidney transplantation at listing may no longer have the same risk profile later. Candidates who were never tested before listing should receive anti-HCV antibody testing by EIA with confirmation by NAT in low-prevalence regions, or direct NAT in high-prevalence settings. A positive NAT should place the candidate on hold and prompt hepatology evaluation and possible treatment.

Patients who achieved a sustained virological response before transplantation should undergo at least annual NAT testing to confirm that the response persists. Relapse likewise requires hold status and referral for possible retreatment. Patients who remain viremic should receive annual assessment of liver disease. In the cited cohort, eight of thirteen patients who underwent repeat biopsy while still waiting showed worsening liver histology, whereas only seven of thirty-one follow-up biopsies obtained after transplantation showed interval worsening. Roth’s evidence thus makes the waiting list an active period of disease progression rather than a neutral pause before surgery.

The surveillance schedule is tied to pathology. Candidates with Metavir stage 1 or 2 fibrosis should have repeat biopsy every five years; those with stage 3 fibrosis require reassessment after three years. Progression to early or established cirrhosis should remove the patient from the kidney-only list and redirect evaluation toward simultaneous liver-kidney transplantation. The system classifies candidates according to antibody status, RNA status, fibrosis stage, and hepatic compensation, but its purpose is not merely bureaucratic: each classification changes access to an organ and the acceptable level of post-transplant risk.

Treatment Before Transplantation

Roth’s work describes a persistent lack of consensus over whether actively viremic candidates should receive antiviral therapy before transplantation. The possible benefits are clinically important. A pretransplant sustained virological response may reduce the subsequent risk of post-transplant diabetes and immune-complex-mediated glomerular disease in the renal allograft. Most patients who achieve sustained response before transplantation do not relapse after immunosuppression is introduced, although evidence remains limited on whether pretransplant viral clearance slows the progression of liver injury itself.

The timing of treatment is decisive because interferon after transplantation is associated with an increased risk of renal-allograft rejection. For that reason, efforts to eradicate HCV should, when possible, be concentrated before transplantation. Yet pretransplant therapy carries its own burdens: interferon produces a wide range of adverse events, nonresponse is common enough to matter, treatment is prolonged and expensive, and patients may need to be excluded from the waiting list while receiving it. Some patients refuse therapy, withdraw from it, or cannot respond.

Roth’s position is consequently not an absolute demand for viral eradication before transplantation. Even patients with positive HCV RNA who are not candidates for treatment should still be offered transplantation when their liver disease permits it, because their expected course is more favorable than remaining on dialysis. In this setting, an HCV-positive donor kidney may offer an additional reduction in waiting time. The clinical decision therefore balances the promise of viral clearance against treatment toxicity, exclusion from the list, organ scarcity, and the demonstrated survival advantage of transplantation.

Transplantation, Survival, and Graft Outcomes

The transplantation chapter associated with Roth distinguishes two comparisons that are often confused. HCV-infected kidney recipients generally have inferior long-term survival compared with recipients without evidence of infection, particularly in studies extending beyond ten years after transplantation. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79 for HCV infection, with part of the excess explained by liver-related death. These findings establish HCV as a long-term hazard, but they do not show that dialysis is safer than transplantation.

When the relevant comparison is transplantation versus remaining on the waiting list, transplantation retains a clear survival advantage. Earlier studies found lower mortality among HCV-positive patients who received a kidney than among those who remained on dialysis or waiting lists. In Roth’s analysis of 175 listed candidates with documented HCV infection, the hazard ratio for death was 2.51 during the first six months after transplantation, then fell to 0.32 during months seven through eighty-four. The early postoperative hazard and the later survival benefit form a sharp temporal contrast: transplantation is not risk-free, but the longer-term alternative is more dangerous.

Roth’s cited evidence also addresses the graft itself. In one comparison, 488 anti-HCV-positive recipients had a 1.53 adjusted relative risk of graft loss compared with 2,877 seronegative recipients. Registry data from Australia and New Zealand found worse five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Loss was more often attributed to glomerulonephritis and chronic allograft nephropathy in the HCV-positive group. Other studies reported nonsignificant decreases in graft loss, so the evidence is not uniform, but the dominant concern is that HCV can affect both patient survival and the durability of the renal allograft.

The chapter also preserves important uncertainty. Many studies classified infection by ELISA rather than more accurate nucleic acid testing and did not perform pretransplant liver biopsies, making it difficult to separate the effects of active virus from preexisting liver injury. Roth’s approach therefore resists treating every anti-HCV-positive recipient as biologically identical. Antibody status, RNA status, liver pathology, immunosuppression, and the duration of follow-up all shape the meaning of the observed outcome.

Positive Donor Kidneys and the Politics of Scarcity

Roth’s broader clinical context includes the controversy over transplanting kidneys from HCV-positive donors. Organ scarcity makes the question unavoidable: HCV-positive kidneys may transmit infection, yet rejecting them can lengthen waiting times for candidates who are already infected and may eventually discard usable organs. The volume notes that many centers never accept such kidneys and that some jurisdictions restrict them technically or legally, even as demand greatly exceeds supply.

For HCV-positive recipients, the potential advantage is measurable. Registry evidence found that recipients of HCV-positive kidneys waited 310 fewer days than the average waiting time at their center and 395 fewer days than comparable recipients who waited for HCV-negative kidneys. Receiving an HCV-positive kidney was independently associated with better survival than remaining on the waiting list, with an adjusted hazard ratio of 0.76. The organ is therefore not described simply as contaminated or inferior; its value depends on the recipient’s infection status, liver condition, treatment options, and the competing danger of prolonged dialysis.

Long-term Spanish data involving 162 HCV-positive recipients of HCV-positive kidneys and 306 HCV-positive recipients of HCV-negative kidneys found no difference in patient survival. Liver-related deaths were rare in both groups—three in the HCV-positive-donor group and two in the comparison group. Although graft survival was lower among recipients of HCV-positive kidneys, the difference was linked to older donor and recipient age and to more frequent pretransplant viremia rather than to donor serology as an independent risk factor. Donor HCV-positive status was not independently associated with death, graft loss, advanced liver disease, or post-transplant diabetes, and no difference appeared in post-transplant glomerular disease.

The policy problem remains stark: HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. Roth’s evidence supports organizational strategies that move suitable organs to appropriate HCV-positive recipients, especially patients who will not receive interferon therapy. At the same time, it keeps the safeguards visible: liver disease must be staged, active infection must be distinguished from prior exposure, and the promise of shorter waiting must be weighed against transmission, immunosuppression, and graft-specific risks.

Narrative and Clinical Significance

David Roth’s role in the volume is that of a clinician-editor who makes medical uncertainty operational. His work does not reduce HCV to a single laboratory result. Instead, it follows the patient through a chain of decisions: antibody screening, NAT confirmation, biopsy-based fibrosis staging, waiting-list hold status, annual surveillance, pretransplant treatment, kidney-only or combined transplantation, and post-transplant monitoring. Each step converts biological information into eligibility, delay, treatment exposure, or access to an organ.

The resulting perspective is both protective and consequential. Screening can identify advanced liver disease before an unsafe kidney-only transplant, while surveillance can reveal deterioration during years of waiting. Pretransplant viral clearance may prevent later complications, yet treatment can itself exclude a patient from the list and expose the patient to adverse effects. An HCV-positive donor kidney may carry a transmissible virus, yet accepting it can shorten waiting and improve survival compared with continued dialysis. Roth’s contribution lies in holding these contradictions together rather than allowing one risk to erase the others.

Across the book, HCV infection becomes a test of how transplantation systems value time, organs, evidence, and patients whose conditions do not fit simple categories. Roth’s repeated presence—as editor, author, investigator, and cited authority—gives that test a distinctly clinical form. The decisive question is not whether HCV makes transplantation dangerous; it does. The decisive question is whether carefully staged liver disease, explicit surveillance, and recipient-specific allocation can make transplantation safer and more life-preserving than the alternatives.